Health
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma – Newswise
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy, which…
-
Noosa News23 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General19 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General13 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General23 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity